ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 56 filers reported holding ADC THERAPEUTICS SA in Q3 2021. The put-call ratio across all filers is 1.30 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $3,041,000 | -0.2% | 124,875 | 0.0% | 3.05% | +23.4% |
| Q1 2021 | $3,048,000 | -24.3% | 124,875 | -0.8% | 2.47% | -19.5% |
| Q4 2020 | $4,028,000 | -9.5% | 125,850 | -6.7% | 3.07% | -12.6% |
| Q3 2020 | $4,451,000 | -29.5% | 134,912 | 0.0% | 3.51% | -20.5% |
| Q2 2020 | $6,315,000 | – | 134,912 | – | 4.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 5,402,041 | $4,845,631 | 1.54% |
| Sio Capital Management, LLC | 3,294,534 | $2,955,197 | 0.92% |
| Redmile Group, LLC | 14,178,045 | $12,717,706 | 0.60% |
| AlphaCentric Advisors LLC | 1,068,468 | $958,416 | 0.54% |
| Vantage Consulting Group Inc | 850,737 | $763,111 | 0.51% |
| Blue Owl Capital Holdings LP | 733,568 | $654,489 | 0.51% |
| Affinity Asset Advisors, LLC | 1,100,000 | $986,700 | 0.28% |
| Frazier Life Sciences Management, L.P. | 1,647,030 | $1,477,386 | 0.10% |
| Indie Asset Partners, LLC | 92,700 | $83,152 | 0.08% |
| GCM Grosvenor Holdings, LLC | 410,888 | $368,567 | 0.07% |